US 11,433,085 B2Granted

Phospholipid compositions

AssigneeMachavert Pharmaceuticals LLC

InventorsJakub Staszak-Jirkovsky, Lukas Kobr, Gregory Miknis, Colleen Hudson, Luca Monfregola, Pavel Jirkovsky, Zbon{hacek over (c)}áková Milada, Jason Duex, Pitchaimani Kandasamy

Life of this patent

Estimating the term…

patentgrep

Loading patent…

Abstract

Compositions involving a modified egg yolk extract for use as an effective anti-cancer agent are described. The modified egg yolk extract involves specific fractions of phosphatidylcholines and sphingomyelins modified and produced from a chemical synthesis applied to the extract that produce a beneficial effect on the inhibition of cancerous cell growth. Methods of administering these compositions are also described.

Claims1

Dependent claims

A method of treating lung cancer in a human patient in need thereof comprising administering to said patient a pharmaceutical composition consisting of a plurality of phosphatidylcholine compounds and one or more pharmaceutically acceptable diluents, excipients, and/or carriers:

wherein said plurality of phosphatidylcholine compounds comprise 1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine and one or more phosphatidylcholines selected from the group consisting of:
1-palmitoleoyl-2-linoleoyl-sn-glycero-3-phosphocholine,
1-palmitoyl-2-α-linolenoyl-sn-glycero-3-phosphocholine,
1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine,
1,2-dilinoleoyl-sn-glycero-3-phosphocholine,
1-palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine,
1-α-linolenoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine,
1-palmitoleoyl-2-oleoyl-sn-glycero-3-phosphocholine,
1-palmitoleoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine,
1-palmitoyl-2-osbodnoyl-sn-glycero-3-phosphocholine,
1-oleoyl-2-arachidonoyl-sn-glycero-3-phosphocholine,
1-oleoyl-2-linoleoyl-sn-glycero-3-phosphocholine,
1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine,
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine,
1-oleoyl-2-docosahexenoyl-sn-glycero-3-phosphocholine,
1,2-dioleoyl-sn-glycero-3-phosphocholine,
1-stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine, and
1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine.

15 more elements

Dependencies are inferred from the claim text.

Facts

Application: 16/653,591Filed 15 Oct 2019 · continuation
Priority: 29 Jun 2016
Published: US 2020/0046744 A113 Feb 2020
Granted: 6 Sep 2022
Term ends: Not estimatedThe source records don’t support an estimate.

Classification10 codes

A61K 31/688
Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols: both hydroxy compounds having nitrogen atoms, e.g.…
A61K 9/0053
Galenical forms characterised by the site of application: mouth and digestive tract, i.e. intraoral and peroral administration
A61K 9/48
Medicinal preparations characterised by special physical form: preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/685
Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols: one of the hydroxy compounds having nitrogen atoms, e.g.…

Family

Application62/356,197Us provisional application · filed 29 Jun 2016
Application62/356,189Us provisional application · filed 29 Jun 2016
Application15/637,126Parent of this continuation · filed 29 Jun 2017
US 2020/0046744 A1Pre-grant publication · published 13 Feb 2020
US 10,493,086 B2Parent of this continuation
US 2018/0000850 A1Published application
US 11,433,085 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key